Allergan is a “free option” for investors looking at Valeant, says Paradigm

Paradigm Capital analyst Alan Ridgeway believes that Valeant Pharmaceuticals is an "acquisition-focused material growth opportunity".

Valeant Pharmaceuticals’ (TSX:VRX) upcoming Q2 may be the first of a number of quarters that show that the company’s acquisition-focused growth strategy is strong and sustainable, says Paradigm Capital analyst Alan Ridgeway. On Thursday, Valeant will report its Q2, 2014 results. The company is following up on a Q1 in which it posted a topline [...]

The street is still underestimating Amaya Gaming, says Global Maxfin’s Garcea

Amaya Gaming CEO David Baazov.

With important regulatory approvals from both the gaming industry and the TSX in the bag on its acquisition of the company that owns the PokerStars and Full Tilt Poker brands, Amaya Gaming (TSX:AYA) is set to unlock considerable value, says Global Maxfin analyst Ralph Garcea. Amaya yesterday announced that it had received thumbs up from [...]

Celestica’s improving margins highlight its Q2 results, says Paradigm


Paradigm analyst Gabriel Leung says improved margins in Celestica’s (TSX:CLS) second quarter overshadow its weaker Q3 guidance. Yesterday, Celestica reported its Q2, 2014 results. The company earned (US) $40.9-million on revenue of $1.47-billion, a topline that was down 2% from last year’s Q2. CEO Craig Muhlhauser took a longer view of the company’s results. “Celestica [...]

NXT Energy Solutions’ future looks bright, says Mackie Research Capital

Mackie Research Capital analyst Raveel Afzaal says his discussions with end users suggest a high correation between anomalies detected by NEXt Energy Solutions' Stress Field Detector technology and seismic surveys.

After some unavoidable regulatory delays and technical reviews, the future is looking bright for NXT Energy Solutions (TSXV:SFD), says Mackie Research Capital analyst Raveel Afzaal. In a research update to clients this morning, Afzaal maintained his “Speculative Buy” recommendation and $1.70 one-year target price on NXT Energy, implying a 31% return from the date of [...]

CGI Group is still undervalued, says Cormark analyst Tse


The valuation gap between CGI Group (TSX:GIB.A) and its more expensively priced peers will begin to tighten because the value creation from its “contrarian” acquisition of Logica will ultimately outpace expectations, says Cormark analyst Richard Tse. Next Wednesday, before market open, CGI will report its Q3, 2014 results. The company is coming off a Q2 [...]

Espial gets buy rating and $4.00 target from Clarus analyst Ofir


A major shift in the way cable is being delivered and consumed is creating a huge opportunity for Espial Group (TSX:ESP), says Clarus Securities analyst Eyal Ofir. In a research report to clients this morning, Ofir initiated coverage of Espial with a “Buy” rating and one-year target of $4.00. Ofir thinks Espial, which has spent [...]

Following soft Q1, Paradigm maintains buy rating on Avante Logixx


Avante Logixx’s (TSX:XX) Q1 revenue decline is disappointing, but the company’s acquisition strategy shows promise, says Paradigm Capital analyst Spencer Churchill. On Monday, Avante Logixx reported its Q1, 2015 results. The company earned $208,055 on revenue of $2,026,260, down 12.8% from the Q1, 2014′s topline. Avante co-CEO George Rossolatos characterized the quarter. “While we are [...]

Paradigm launches coverage of Tecsys with a Buy rating, $10.00 target

Public Law 113-54, which was signed into law by President Obama last November, establishes a national track and trace system for prescription medication that could accelerate an upgrade cycle of technology throughout the healthcare supply chain, says Paradigm Capital analyst Gabriel Leung.

There is a multi-billion dollar market opportunity in automating the healthcare supply chain and Tecsys (TSX:TCS) is positioned to grab a share of it, says Paradigm Capital analyst Gabriel Leung. In a research report to clients this morning, Leung initiated coverage of Tecsys with a “Buy” rating and a one-year target of $10.00, implying a [...]

Clarus launches coverage of ViXS with Buy rating, $3.30 target


The 4K TV market represents “a significant opportunity” and Toronto’s ViXs Systems (TSX:VXS) is poised to grab a meaningful share of it, says Clarus Securities analyst Eyal Ofir. In a research report to clients today, Ofir launched coverage of ViXS with a “Buy” rating and a one-year price target of $3.30, implying a return of [...]

Should the City of Vancouver really be in the venture capital business?


A proposal currently in front of Vancouver City Council would see it establish a venture capital fund to aid a sector it sees as “diffuse, poorly connected and relatively risk-averse” and suffers from a lack of access to capital. The plan would see the Vancouver Economic Commission budget increased in 2015, 2016 and 2017 to [...]